Featured

From Bloomberg

“April 14 (Bloomberg) — Competition for the Botox shot, America?s most popular cosmetic procedure, was delayed as U.S. drug regulators discuss labeling and a strategy for evaluating and mitigating risks of the new wrinkle smoother.

Medicis Pharmaceutical Corp. and Ipsen SA, which developed the experimental Reloxin product, are in talks with the Food and Drug Administration, Boulogne-Billancourt, France-based Ipsen said today in a statement. The injection relaxes the muscles that cause forehead lines using a type of botulinum toxin similar to the one in Allergan Inc.?s Botox. The delay should be a matter of weeks, according to brokerage Aurel BGC.”

This isn’t the first time Reloxin has gotten delayed; early last year, the FDA rejected Medicis’ initial application, citing a paperwork snafu.

Another Delay for Reloxin